ORIGINAL ARTICLE

Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma

H Sartelet, E Lagonotte, M Lorenzato, I Duval, C Lechki, C Rigaud, J Cucherousset, A Durlach, O Graesslin, P Abboud, M Doco-Fenzy, C Quereux, B Costa, M Polette, J-N Munck, P Birembaut

J Clin Pathol 2005;58:864–871. doi: 10.1136/jcp.2004.024224

See end of article for authors' affiliations

Correspondence to:
Dr H Sartelet, Laboratoire
d'Histologie, Faculté de
Médecine, 51, Rue
Cognacq-Jay, 51095
Reims Cedex, France;
hsartelet@chu-reims.fr

Accepted for publication
6 January 2005

Background: HER-2 amplification is an important prognostic biomarker and treatment determinant in breast carcinoma.

Aims: To correlate immunocytochemical (ICC) expression of HER-2 and gene amplification determined by chromogenic in situ hybridisation (CISH) using liquid based cytology (LBC) with immunohistochemistry (IHC) and CISH using histological samples of the same breast carcinomas.

Methods: Frozen sections and cytobrushings of 103 breast carcinomas were analysed. Four techniques were performed on each tumour: two on LBC samples (ICC, and CISH, both graded as positive, indeterminate, or negative) and two on histological samples (IHC and CISH). Two cell lines (MCF-7, negative; BT 474, positive) were used as controls for cytological analysis. A complementary fluorescence in situ hybridisation technique was carried out in histological samples with low amplification (4–10 dots/nucleus).

Results: Interobserver agreement for the four techniques calculated by the κ coefficient indicated a substantial agreement. Nine cases failed in cytology because of poor cellularity. Among 94 cases, 19 were amplified; 73, 12, and 9 tumours were scored 0 or 1+, 2+, and 3+, respectively by IHC and 75, 13, and 6, respectively, by ICC. CISH found no amplification in 72 tumours. Correlations between the IHC and CISH results in the histological and cytological samples were always significant.

Conclusions: Her-2 status could be determined in LBC samples and correlated well with reference histological methods using in situ hybridisation. ICC was less reliable because of the presence of the cytoplasmic membrane. However, these results should be confirmed by a large multicentre study.

Breast carcinomas are the most frequent tumours in women. In several countries, mammographic screening allows the early diagnosis of tumours. However, when a tumour is suspected, morphological analysis alone can establish the diagnosis of carcinoma. In this context, guided fine needle aspiration has become increasingly popular for obtaining tissue specimens for the diagnosis of malignant breast diseases.

"The importance of measuring HER-2 gene amplification and its overexpression in breast carcinoma is clearly established"

HER-2/neu, a protooncogene located on chromosome 17q, encodes a transmembrane tyrosine kinase with substantial homology to the epidermal growth factor receptor.^{1,2} The importance of measuring HER-2 gene amplification and its overexpression in breast carcinoma is clearly established—it is associated with poor prognosis,^{3,4} short survival,⁵ and response to specific treatment with Trastuzumab.⁶ Different techniques have been used to measure the cellular concentration of HER-2 in biopsies and surgical samples, but currently the most frequently used methods are immunohistochemistry (IHC)⁷ and in situ hybridisation.⁸ A large number of studies have compared both methods to evaluate HER-2 status, with advantages and pitfalls for each one. It is now thought that HER-2 determination is most efficient using IHC as the method of choice, with in situ hybridisation being performed for cancers with indeterminate results (2+ score).⁹ Several in situ hybridisation techniques are available.

Fluorescence in situ hybridisation (FISH) can be carried out using either a single colour (HER-2 probe only) or the more frequently used dual colour technique (using HER-2 and chromosome 17 centromere probes simultaneously).¹⁰ The main disadvantage of using FISH in clinical diagnostics is the need for fluorescence microscopy, which is not available in most routine diagnostic laboratories. Moreover, the evaluation of FISH requires a modern epifluorescence microscope equipped with high quality immersion objectives and multi-band pass fluorescence filters. In addition, because the fluorescent signals fade within a few weeks, the hybridisation results must be recorded with expensive digital cameras. Thus, to overcome these practical limitations, chromogenic in situ hybridisation (CISH) was recently introduced, in which the DNA probe is detected using a simple IHC-like peroxidase reaction.¹¹

Evaluation of HER-2 status with fine needle aspiration from primary breast carcinoma is important in clinical practice. Different techniques have been used to measure the cellular concentration of HER-2: enzyme immunoassay,¹² immunocytochemistry (ICC),^{13,14} and in situ hybridisation.^{15,16} Recent studies showed that overexpression of HER-2 can be detected successfully in routine conventional cytological specimens from breast cancer and other neoplasms,¹⁴ and have shown that FISH can be used successfully in cytological samples to evaluate HER-2 amplification and

Abbreviations: CI, confidence interval; CISH, chromogenic in situ hybridisation; FISH, fluorescence in situ hybridisation; ICC, immunocytochemistry; IHC, immunohistochemistry; LBC, liquid based cytology; SSC, standard saline citrate

compares well with histological analysis.^{15 16} Recently, LBC has been introduced for mammary aspirates. There is a good correlation between LBC and conventional breast fine needle aspirate preparations.¹⁷ Moreover, LBC offers the possibility of adjunctive investigations (ICC and in situ hybridisation) on the same homogeneous material. Therefore, it will be useful to evaluate HER-2 status by this new cytological method because it is already possible using conventional routine cytology specimens.

Thus, the aim of our study was to analyse these two new techniques together: LBC and CISH to evaluate HER-2 status. Consequently, we will correlate these new techniques with conventional techniques: immunohistochemistry (IHC) and CISH using histological samples of the same breast carcinomas. In addition, ICC analysis of HER-2 expression will also be carried out on LBC samples.

MATERIALS AND METHODS

Patients

A prospective study was carried out at two medical centres in Reims, France—the Medical School Hospital and the Cancer Centre (Jean Godinot Institute)—between January 2002 and October 2003. Patients underwent an excisional biopsy, which allowed the diagnosis of invasive breast carcinoma. A frozen section of each tumour was obtained to establish the diagnosis of breast carcinoma and then a cytobrush sample was taken from the fresh tumour and rinsed in ThinPrep transport solution (Preservcyt; Cytec, Boxborough, Massachusetts, USA). The histological and cytological samples were gathered together and analysis took place one week to three months after surgery. The stained slides were analysed microscopically by two independent observers (HS and PB). The degree of interobserver agreement was measured using the κ coefficient (0, no agreement; 1, perfect agreement).

Histology

Tissue specimens

Formalin fixed samples were obtained from patients with breast carcinoma. For each patient, one block containing the central part of the tumour was selected for IHC and in situ hybridisation. Tumour stage and histological grade were determined for each patient.

Immunohistochemistry

Sections (4 μ m thick) were dewaxed and rehydrated in graded alcohols. Antigen retrieval was achieved by heating slides in a water bath at 98°C for 10 minutes in citrate buffer (pH 6.0). After cooling the sections to room temperature, endogenous peroxidases were quenched with 0.3% H₂O₂ in water. Monoclonal antibody NCL-CB11 from Novocastra Laboratories (Newcastle upon Tyne, UK) was applied at a dilution of 1/500 and incubated for 30 minutes at room temperature. Immunohistochemical staining was performed using the streptavidin biotin kit (LSAB II; Dako, Glostrup, Denmark). The peroxidase was visualised using 3-amino-9-ethylcarbazole as chromogen. The slides were rinsed with water, counterstained with haematoxylin, and mounted.

IHC scoring was based on the membrane immunoreactivity: no staining or membrane staining in less than 10% of the tumour cells was considered negative (0); faint/barely perceptible membrane staining in more than 10% of the tumour cells was defined as 1+; weak to moderate complete membrane staining in more than 10% of the tumour cells was defined as 2+; and strong complete membrane staining in more than 10% of the tumour cells was defined as 3+. As described previously,⁹ the results were divided into three categories: negative or without overexpression (0 or 1+), positive with overexpression (3+) (fig 1D), and indeterminate (2+). All histological tests were evaluated without knowledge of the cytological result.

Figure 1 Immunohistochemistry in invasive ductal carcinoma. HER-2 is characterised by membranous staining. Sections were counterstained with haematoxylin. (A, B) No overexpression of HER-2 (0 and 1+, respectively); (C) intermediate positivity (2+); (D) overexpression (3+).

CISH and FISH

Probes

The HER2 gene status was determined using the digoxigenin labelled SPOT-Light® HER2 DNA probe (Zymed, South San Francisco, California, USA). A biotin labelled chromosome 17 centromere probe (Zymed) was used for those tumours with six to 10 HER2 gene copies/nucleus.

FISH and CISH procedure

FISH and CISH were performed on 4 µm thick tissue sections mounted on Superfrost Plus microscope slides (Fisher, Pittsburgh, Pennsylvania, USA). The slides were baked overnight at 38°C and then dewaxed twice for 10 minutes in xylene, for five minutes in ethanol, and three times in water. Tissue sections were placed in a ceramic coplin jar containing CISH pretreatment buffer (SPOT-Light tissue pretreatment kit; Zymed) and loosely capped. They were heated at 95°C for 10 minutes in a bath water and then washed immediately with deionised water. Enzyme digestion was carried out by covering the section with prewarmed 37°C pepsin (SPOT-Light tissue pretreatment kit; Zymed) and incubating at 37°C for 10 minutes. The slides were then washed with deionised water, dehydrated with graded ethanol, and air dried. Next, 10 µl of ready to use chromosome 17 centromere probe was applied to the centre of the 20 × 20 mm coverslip. After sealing the edges of the coverslips with rubber cement, the tissue sections and probes were denatured at 95°C for six minutes in a water bath and for one minute on crushed ice. Hybridisation was carried out in a drying oven at 37°C overnight. Stringent washing was carried out with 0.5× standard saline citrate (SSC) at 75°C for five minutes.

CISH

Endogenous peroxidase activity was blocked in 3% H₂O₂ for 10 minutes. Non-specific background was eliminated by incubating the tissue sections in CAS-Block (Zymed). This was followed by incubation with fluorescein isothiocyanate conjugated mouse anti-digoxigenin antibody for 45 minutes at room temperature and then incubation with horseradish peroxidase conjugated goat anti-fluorescein isothiocyanate antibody for 45 minutes at room temperature. Development was carried out with diaminobenzidine for 20 minutes. Tissue sections were counterstained with haematoxylin, dehydrated, and coverslipped. Positive controls were included in each staining run. A case of infiltrating ductal carcinoma, positive for the HER-2/neu oncoprotein by IHC analysis and amplified by CISH, was used as a positive control and non-neoplastic breast tissue was used as a negative control. In most cases, non-neoplastic elements served as internal controls.

The CISH sections were evaluated using a microscope with a ×40 dry objective (Zeiss axioplan; Carl Zeiss AG, Jena, Germany). As described by Tanner *et al*,¹¹ amplification was defined as six or more signals/nucleus in more than 50% of the cancer cells, or when a large gene copy cluster was seen.¹¹ Unaltered gene copy was defined as 1–5 copies/nucleus. In tumours with a borderline copy number count (6–10 copies/nucleus in more than 50% of cells), an adjacent serial section was hybridised with a chromosome 17 centromere probe (Zymed) for comparison.

FISH

In these cases, the biotin labelled chromosome 17 centromere probe was detected with sequential incubation with alexa red conjugated streptavidin for 45 minutes at room temperature. The mounting medium containing DAPI (Vectashield; Vector Laboratories, Burlingame, California, USA) was removed by washing with phosphate buffered saline and Tween 20.

The FISH results were evaluated using a microscope (Zeiss axioplan; Carl Zeiss AG) equipped with a ×100 oil immersion objective and DAPI/rhodamine filter sets (Carl Zeiss AG). HER-2 amplification was determined as the ratio of HER-2 CISH to chromosome 17 centromere FISH signal counts. Ratios < 2 denoted no amplification, and those between 2 and 5 denoted low level amplification.

In our study, true amplification was found in two situations: high level amplification was defined as greater than 10 discrete copies/nucleus detected by CISH in histology and low level amplification was defined as a HER-2 to chromosome 17 centromere signal count ratio between 2 and 5.

Cytology

For each case, two thin layer samples were prepared using the ThinPrep technique (Cytec) and post-fixed in absolute ethanol for 24 hours. Two breast cancer cells lines fixed in Preservcyt were used as positive (BT 474¹⁸) and negative (MCF-7¹⁹) controls for HER-2 amplification.

Immunocytochemistry

After post-fixation of the cytological slides and antigen unmasking for 10 minutes at 98°C in citrate buffer (pH 6.0), blocking of endogenous peroxidase was carried out in 3% hydrogen peroxide for 10 minutes. The dilutions and incubation times of the primary antibody and the secondary reagents were the same as for IHC. Immunopositivity was scored quantitatively on cytological samples as for the histological samples. The evaluation of HER-2 amplification was carried out in at least 100 cells.

CISH

After post-fixation, the slides were air dried and placed in CISH pretreatment buffer (SPOT-Light tissue pretreatment kit; Zymed) at 75°C for 10 minutes, followed by washing in 2× SSC and incubation at 37°C for five minutes in prewarmed pepsin at 37°C (SPOT-Light tissue pretreatment kit; Zymed). The slides were then washed with 2× SSC and 10 µl of the HER-2 probe solution was placed on the centre of a 20 × 20 mm coverslip. After sealing the edges of the coverslips with rubber cement, the tissue sections and the probes were denatured at 80°C for three minutes. Hybridisation was carried out at 37°C overnight. The dilutions and incubation times of the secondary reagents were the same as in CISH for histology. The ICC and CISH techniques were done in batches of 10 slides with appropriate positive and negative controls. The evaluation of amplification was carried out on at least 100 cells.

Statistical analysis

The χ^2 test was used to evaluate the correlations between IHC, ICC, and CISH in histological and cytological samples. A p value < 0.05 was considered to be significant. All the tests were performed with the Stat View program (Abacus Concepts, Berkeley, California, USA).

The analytical performance of ICC and CISH in cytological samples was also analysed for specificity, sensitivity, and negative and positive predictive values.

RESULTS

In total, 103 cases were assessed by IHC and ICC for HER-2 protein expression and by CISH in histological and in cytological samples for gene amplification.

CISH cytology and/or ICC analysis failed in nine cases; five because of a lack of cells, and four because of inadequate digestion despite using several thin layer preparations and an optimised protocol. Therefore, four results (IHC and CISH in

Table 1 Cohort characteristics

Variable	N	%
Patients, total	94	
Age (years)		
<35	3	3.2
36–50	26	27.6
51–54	11	11.8
>55	54	57.4
Histology		
Ductal	78	83.0
Lobular	14	14.9
Other	2	2.1
Grade		
1	22	23.4
2	48	51.1
3	24	25.5
Tumour size (mm)		
1–10	12	11.6
11–20	49	47.6
21–50	38	36.9
>50	4	3.9

histological samples; ICC and CISH in cytological samples) are available for 94 cases.

Clinical features of the patient population

The patients' ages ranged from 28 to 84 years with a median of 58.88 years (table 1). Most tumours (78 of 94) were pure invasive ductal carcinomas, whereas 14 were lobular carcinomas and two were mucinous carcinomas. Among the 94 carcinomas, 24 were poorly differentiated (Bloom 3), 48 were moderately differentiated (Bloom 2), and 22 were well differentiated (Bloom 1).

Histology

Interobserver agreement for the two techniques calculated by generalised κ values indicated a substantial agreement (0.68 to 0.80).

Using IHC, among 94 cases, 73 were negative or without overexpression of HER-2 (0 or 1+) (fig 1A, B), 12 were indeterminate (2+) (fig 1C), and nine were positive with HER-2 overexpression (3+) (fig 2D).

With CISH, 72 tumours showed no amplification, with 1–5 gene copies/nucleus (fig 2A) and 11 showed high amplification (fig 2C). Eleven tumours had 6–10 copies of the HER-2

Figure 2 Examples of chromogenic in situ hybridisation for the HER-2 oncogene and fluorescence in situ hybridisation (FISH) for the chromosome 17 centromere in breast cancer. (A) A tumour with one or two clearly identifiable copies of the HER-2/neu gene (no amplification). (B) This tumour contained six to 10 copies of HER-2/neu gene/nucleus in more than 50% of the cells. (C) Typical high amplification of the HER-2/neu gene appears as a peroxidase positive cluster of gene copies. In these tumours, the FISH technique for the chromosome 17 centromere produced two types of results: (D) two spots showing low amplification, and (E) six to 10 copies/nucleus corresponding to aneuploidy and no amplification.

Figure 3 Immunocytochemistry for the HER-2 protein in liquid based cytology samples from patients with breast cancer. (A) Negative control (MCF7), (B) positive control (BT474), (C) sample with no expression (0), (D) sample with no expression (+1), (E) sample with indeterminate expression (2+), and (F) sample with overexpression of the protein.

gene/nucleus in more than 50% of cells (fig 2B). In these cases, FISH analysis showed low amplification in eight cases, with a HER-2 to chromosome 17 centromere signal count ratio between 2 and 5 (fig 2D) and three cases of false amplification with a ratio under 2 (fig 2E). In summary, HER-2 was amplified in 19 of 94 cases, 11 had high level and eight had low level amplification. All amplified cases were ductal carcinomas; nine were poorly differentiated (Bloom 3), four moderately differentiated (Bloom 2), and six were well differentiated (Bloom 1).

Liquid based cytology

Interobserver agreement for the two techniques calculated by generalised κ values indicated a substantial agreement (0.71 to 0.75).

Immunocytochemical analysis

Among 94 cases, 75 had an ICC score of 0 or 1+ (fig 3C, D). None of these cases showed gene amplification, and 72 were negative (0, 1+) and three indeterminate (2+) by IHC (table 2).

Thirteen cases were categorised as indeterminate (2+) (fig 3E). Six showed low and seven high gene amplification (table 3), eight were indeterminate with IHC, four positive, and one negative (table 2).

Six cases overexpressed HER-2 (3+) (fig 3F). One of these cases had low and five had high gene amplification. One was indeterminate and five were positive (3+) by IHC (table 2).

CISH

The HER-2 gene was amplified in 11 of the 94 cases (fig 4E). Two of these cases were indeterminate by IHC and nine were positive. All these cases were amplified in the histological samples, 10 had low and one had high amplification.

In addition, 11 cases showed low amplification (fig 4D). However, in the histological samples, eight showed low amplification and three were aneuploid. Four were negative and seven were indeterminate by IHC.

Finally, 72 tumours were not amplified (fig 4C) by CISH in either the cytological or histological samples. Sixty nine of these cases were negative with IHC and three were indeterminate.

Comparison between histological and cytological analyses

We correlated the results obtained from both the histological and cytological techniques. There was a significant correlation between the IHC results and the techniques used on the cytological samples (ICC and CISH) (χ^2 test, $p < 0.01$; table 2).

Table 2 Relation between HER-2 overexpression determined by immunohistochemistry and immunocytochemistry and gene amplification detected by CISH in cytology

	Immunohistochemistry			Total
	Negative (0, 1+)	Indeterminate (2+)	Positive (3+)	
Immunocytochemistry				
Negative (0, 1+)	72	3	0	75
Indeterminate (2+)	1	8	4	13
Positive (3+)	0	1	5	6
Total	73	12	9	94
CISH in cytology				
No amplification (2-6)	69	3	0	72
Low amplification (6-10)	4	7	0	11
High amplification (>10)	0	2	9	11
Total	73	12	9	94

CISH, chromogenic in situ hybridisation.

Table 3 Relation between HER-2 gene amplification determined by CISH in histology and CISH in cytology and protein overexpression detected by immunocytochemistry

	CISH in histology			Total
	No amplification (2-6)	Low amplification (6-10)	High amplification (>10)	
Immunocytochemistry				
Negative (0, 1+)	72	3	0	75
Indeterminate (2+)	0	6	7	13
Positive (3+)	0	1	5	6
Total	72	10	12	94
CISH in cytology				Totals
No amplification (2-6)	72	0	0	72
Low amplification (6-10)	0	11	0	11
High amplification (>10)	0	1	10	11
Total	72	12	10	94

CISH, chromogenic in situ hybridisation.

There was also a significant correlation between the CISH results using histological samples and the techniques used on the cytological samples (ICC and CISH) (χ^2 test, $p < 0.01$; table 3).

When CISH for the HER-2 probe together with FISH for the chromosome 17 centromere using histological samples is taken as the standard testing method, the positive predictive value of positive ICC scores (3+) was 100% and the negative predictive value of negative ICC scores (0 or 1+) was 100%. The sensitivity and specificity of ICC was also calculated. The analyses were performed with or without the tumour group that had indeterminate (2+ score) results. The sensitivity with 3+ only was 31% (95% confidence interval (CI), 21.6% to 40.3%), and with 3+ and 2+ it was 100%; specificity was always 100%. The same comparisons were done with CISH using cytological samples, with a limit of more than six copies of the HER-2 gene/nucleus. The sensitivity was 100%, the specificity 96% (95% CI, 92% to 99.9%), the positive predictive value was 86.4% (95% CI, 79% to 93%), and the negative predictive value was 100%.

DISCUSSION

Conventional fine needle aspiration is often now complemented by LBC aspiration. When a series of excised palpable breast masses was analysed with these two techniques, LBC provided greater cellularity and better nuclear detail than conventional smears and was as sensitive in identifying the tumorous cells as conventional fine needle aspiration.²⁰ However, LBC is less specific, although this observation was not significant.²¹ In our study, we did not carry out breast aspiration because the cytobrush technique produced optimal

results in our breast surgical specimens. Moreover, a preliminary study found no difference between cytobrush and aspiration samples in the morphology of the cells, only in the amount of material obtained and the number of tumorous cells isolated. However, our study shows clearly that in breast carcinoma there is a highly significant correlation between the reference technique—in situ hybridisation using histological samples—and the analysis of HER-2 status in LBC samples,¹⁶ with the same problem of discriminating between high grade in situ and invasive carcinoma.

ICC on ThinPrep processed fine needle breast aspirates has been used previously to evaluate oestrogen and progesterone receptor numbers and showed a good correlation with the reference technique of enzyme immunoassay.²² This technique can be performed on samples that have been preserved for several days in Preservcyt with a good correlation with newly prepared specimens.²³ In our study, the preservation of the cells was also adequate. We were able to perform ICC up to three months after fixation with optimal cellular reproducibility. However, in nine cases the number of cells was too low to perform all the techniques, in particular ICC. The number of cases with indeterminate expression of the HER-2 protein (2+) using ICC and cytological samples was slightly higher than when using IHC and histological samples (13 versus 12). Because the presence of the cytoplasmic membrane results in dilution of the signal, overexpression of this protein was better determined in histological sections than in cytological samples (nine versus six). In contrast, however, automated image analysis can be applied to cytological samples,²⁴ so that a quantitative signal can be obtained.

Figure 4 CISH analysis of HER-2 gene amplification in thin layer cytology breast cancer samples. (A) Negative control with two spots/nucleus (MCF-7), (B) positive control with more than 10 spots/nucleus (BT474), (C) sample with no amplification (two spots), (D) sample with low amplification (6–10 spots/nucleus), (E) sample with high amplification (> 10 spots/nucleus).

“Our study shows clearly that in breast carcinoma there is a highly significant correlation between the reference technique—in situ hybridisation using histological samples—and the analysis of HER-2 status in liquid based cytology samples”

In situ hybridisation of LBC samples is a recently developed technique, which was first used in cervical cytology, in particular to detect human papillomaviruses.²⁵ A recent study reported that in situ hybridisation and ICC could be performed on the same cervical cytology sample.²⁶ FISH can be used for the detection of aneuploidy in other types of cytological samples, such as LBC urine samples.²⁷ In cytological samples, in situ hybridisation performed on whole nuclei provides the most accurate estimation of gene and chromosome copy numbers because nuclear truncation artifacts are avoided, resulting in accurate gene to chromosome ratios.²⁸ Moreover, truncation might result in a considerable underestimation of gene copy. Indeed, in our study, one case showed low amplification in the histological sample but more than 10 copies of the gene in the cytological sample. Nonetheless, globally there was a good correlation between in situ hybridisation using histological and cytological samples.

FISH measures the number of gene copies in cancer cell nuclei. When dual colour hybridisation probes (using HER-2

and chromosome 17 centromere probes simultaneously) are used, it enables true HER-2 amplification to be distinguished from chromosomal aneuploidy. However, this double hybridisation is useful only for cases with poor amplification (six to 10 spots/nucleus)—only 11 tumours in our study. In most of these cases (eight of 11), the tumours had true low amplification and only three cases showed false amplification. In the rare cases where it was necessary, we used FISH to determine the number of copies of chromosome 17 in the tumour cell nuclei, but only in the histological sections because of the lack of cells in the cytological samples. CISH uses a simple IHC-like peroxidase reaction and seems to be a good alternative to FISH. Previous studies have clearly shown that CISH can provide a very useful, accurate, and practical alternative for determination of HER-2 status in archival formalin fixed breast cancer samples.^{11 29 30} Our present study shows that CISH alone or associated with FISH (in rare cases with six to 10 copies of the HER-2 gene) can provide a good evaluation of HER-2 status in histological or LBC samples.

In conclusion, LBC enables an accurate evaluation of HER-2 amplification to be made, particularly when using in situ hybridisation, because in contrast to histology it is performed on whole nuclei. ICC was less reliable because of the presence of the entire cytoplasmic membrane. LBC of breast fine needle aspirates could also be used to evaluate HER-2 status as a guide to the usefulness of treatment with Trastuzumab.

Take home messages

- HER-2 status could be determined in liquid based cytology (LBC) samples and correlated well with the reference histological methods (immunohistochemistry and in situ hybridisation) using chromogenic in situ hybridisation
- Immunocytochemistry on LBC samples was less reliable because of the presence of the cytoplasmic membrane
- These results should be confirmed by a large multi-centre study

ACKNOWLEDGEMENTS

We gratefully acknowledge Cytoc, Boxborough, Massachusetts, USA for supplying the ThinPrep kits without charge. We thank the Pol Bouin laboratory personnel and particularly Mrs Bouttens and Mrs Evrard for their support and assistance. Supported by Programme Hospitalier de Recherche Clinique (PHRC regional 2001) from the French Health Ministry and by Roche SA Neuilly-sur-seine France.

Authors' affiliations

H Sartelet, E Lagonotte, M Lorenzato, I Duval, C Lechki, J Cucherousset, A Durlach, P Birembaut, Laboratoire Pol Bouin, Centre Hospitalier et Universitaire de Reims, 45, Rue Cognacq-Jay, 51092 Reims Cedex, France

C Rigaud, P Abboud, B Costa, J-N Munck, Institut Godinot Reims, 1 rue du Général Koenig, 51100 Reims, France

O Graesslin, C Quereux, Service de Gynécologie Obstétrique, Centre Hospitalier et Universitaire de Reims

M Doco-Fenzy, Service Cytogénétique, Centre Hospitalier et Universitaire de Reims

M Polette, Unité INSERM U514, rue Cognacq Jay, 51092 Reims, France

REFERENCES

- 1 **Brandt-Rauf PW**, Pincus MR, Carney WP. The c-erb B-2 protein in oncogenesis: molecular structure to molecular epidemiology. *Crit Rev Oncol* 1994;**5**:313–29.
- 2 **Coene ED**, Schellhout V, Winkler RA, *et al*. Amplification units and translocation at chromosome 17q and c-erbB-2 overexpression in the pathogenesis of breast cancer. *Virchows Arch* 1997;**430**:365–72.
- 3 **Farabegoli F**, Ceccarelli C, Santini D, *et al*. c-erbB-2 over-expression in amplified and non-amplified breast carcinoma samples. *Int J Cancer* 1999;**84**:273–7.
- 4 **Harbeck N**, Ross JS, Yurdseven S, *et al*. HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer. *Int J Oncol* 1999;**14**:663–71.
- 5 **Slamon DJ**, Clark GM, Wong SG, *et al*. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 1987;**235**:177–82.
- 6 **Slamon DJ**, Leyland-Jones B, Shak S, *et al*. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* 2001;**344**:783–92.
- 7 **Vincent-Salomon A**, MacGrogan G, Couturier J, *et al*. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEPICs study. *Histopathology* 2003;**42**:337–47.
- 8 **Press MF**, Bernstein L, Thomas PA, *et al*. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. *J Clin Oncol* 1997;**15**:2894–904.
- 9 **Yaziji H**, Goldstein LC, Barry TS, *et al*. HER-2 testing in breast cancer using parallel tissue-based methods. *JAMA* 2004;**291**:1972–7.
- 10 **Kallioniemi OP**, Kallioniemi A, Kurisu W, *et al*. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. *Proc Natl Acad Sci U S A* 1992;**89**:5321–25.
- 11 **Tanner M**, Gancberg D, Di Leo A, *et al*. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. *Am J Pathol* 2000;**157**:1467–72.
- 12 **Wu JT**, Zhang P, Bentz JS. Quantification of HER2 oncoprotein in fine-needle aspirates of the breast. *Ann Clin Lab Sci* 2000;**30**:49–56.
- 13 **Nizzoli R**, Bozzetti C, Crafa P, *et al*. Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas. *Diagn Cytopathol* 2003;**28**:142–6.
- 14 **Mitteldorf CA**, Leite KR, Meirelles MI, *et al*. Overexpression of HER2/neu oncoprotein in cytologic specimens. *Acta Cytol* 2004;**48**:199–206.
- 15 **Moore JG**, To V, Patel SJ, *et al*. HER-2/neu gene amplification in breast imprint cytology analyzed by fluorescence in situ hybridization: direct comparison with companion tissue sections. *Diagn Cytopathol* 2000;**23**:299–302.
- 16 **Bofin AM**, Ytterhus B, Martin C, *et al*. Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma. *Am J Clin Pathol* 2004;**122**:110–19.
- 17 **Veneti S**, Daskalopoulou D, Zervoudis S, *et al*. Liquid-based cytology in breast fine needle aspiration. Comparison with the conventional smear. *Acta Cytol* 2003;**47**:188–92.
- 18 **Baselga J**, Norton L, Albanell J, *et al*. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. *Cancer Res* 1998;**58**:2825–31.
- 19 **Sarup JC**, Johnson RM, King KL, *et al*. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. *Growth Regul* 1991;**1**:72–82.
- 20 **Biscotti CV**, Hollow JA, Toddy SM, *et al*. ThinPrep vs. conventional smear cytologic preparations in analyzing fine-needle aspiration specimens from palpable breast masses. *Diagn Cytopathol* 1999;**21**:137–41.
- 21 **Perez-Reyes N**, Mulford DK, Rutkowski MA, *et al*. Breast fine-needle aspiration: a comparison of thin-layer and conventional preparation. *Am J Clin Pathol* 1994;**102**:349–53.
- 22 **Leung SW**, Bedard YC. Estrogen and progesterone receptor contents in ThinPrep-processed fine-needle aspirates of breast. *Am J Clin Pathol* 1999;**112**:50–6.
- 23 **Tabbara SO**, Sidawy MK, Frost AR, *et al*. The stability of estrogen and progesterone receptor expression on breast carcinoma cells stored as PreservCyt suspensions and as ThinPrep slides. *Cancer* 1998;**84**:355–60.
- 24 **Rhodes A**, Borthwick D, Sykes R, *et al*. The use of cell line standards to reduce HER-2/neu assay variation in multiple European cancer centers and the potential of automated image analysis to provide for more accurate cut points for predicting clinical response to trastuzumab. *Am J Clin Pathol* 2004;**122**:51–60.
- 25 **Schiller CL**, Nickolov AG, Kaul KL, *et al*. High-risk human papillomavirus detection: a split-sample comparison of hybrid capture and chromogenic in situ hybridization. *Am J Clin Pathol* 2004;**121**:537–45.
- 26 **Cheung AN**, Chiu PM, Tsun KL, *et al*. Chromosome in situ hybridisation, Ki-67, and telomerase immunocytochemistry in liquid based cervical cytology. *J Clin Pathol* 2004;**57**:721–7.
- 27 **Skacel M**, Pettay JD, Evangelos KT, *et al*. Validation of a multicolor interphase fluorescence in situ hybridization assay for detection of transitional cell carcinoma on fresh and archival thin-layer, liquid-based cytology slides. *Analyt Quant Cytol Histol* 2001;**23**:381–7.
- 28 **Visscher DW**, Wallis T, Ritchie CA. Detection of chromosome aneuploidy in breast lesions with fluorescence in situ hybridization: comparison of whole nuclei to thin tissue sections and correlation with flow cytometric DNA analysis. *Cytometry* 1995;**21**:95–100.
- 29 **Isola J**, Tanner M, Forsyth A, *et al*. Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridisation. *Clin Cancer Res* 2004;**10**:4793–8.
- 30 **Dandachi N**, Dietze O, Hauser-Kronberger C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. *Lab Invest* 2002;**82**:1007–14.